# Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5

Study · id `cardio:ct-nct06901960` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06901960](<https://clinicaltrials.gov/study/NCT06901960>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06901960

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1066 participants.

## Technical summary

Registry record NCT06901960. Randomized; no masking; primary purpose prevention. Start 2025-04-02 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Not applicable
- Enrolled: 1066 participants (planned count; ClinicalTrials.gov record NCT06901960, source copy `cardio:ctgov-nct06901960-2026-11-12`, retrieved 2026-11-18)
- Started: 2025-04-02 (actual) (ClinicalTrials.gov record NCT06901960, source copy `cardio:ctgov-nct06901960-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06901960, source copy `cardio:ctgov-nct06901960-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT06901960, source copy `cardio:ctgov-nct06901960-2026-11-12`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06901960, source copy `cardio:ctgov-nct06901960-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06901960-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Monitoring Hyperkalemia Using Point-of-care AI-enabled ECG Device Among Patients With Chronic Kidney Disease Stages 3b-5
- Acronym: POCKET
- Condition: Chronic Kidney Disease (Stages 3b-5)
- Intervention (Device): A mobile artificial intelligence-enhanced electrocardiogram device estimating plasma potassium categories (&lt;5 mmol/L, 5 - &lt;5.5 mmol/L, 5.5 - &lt;6.0 mmol/L and ≥ 6.0 mmol/L)
- Lead sponsor: Peking University First Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Peking University First Hospital (`cardio:org-peking-university-first-hospital`)

## Provenance

Content hash: cae9787b5256b0f64193476a2d3dbfd903e64a1a7510d9568aad7165381cfe16
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
